OS Therapies Schedules OST-HER2 Pharmacodynamic Response Biomarker Conference Call on April 30, 2026 at 8:30am ET
OS Therapies announced a conference call for April 30, 2026, to discuss data supporting a PCT international application for its OST-HER2 pharmacodynamic biomarker, which is expected to support early market access via Accelerated Approval in the U.S. and Conditional Marketing Authorizations in Europe, the UK, and Australia. The company outlined a busy regulatory schedule for the remainder of Q2 2026, including two U.S. FDA meetings and one UK MHRA meeting, alongside follow-ups with the EU EMA and Australian TGA.
Key figures
- Drug Name
- OST-HER2
- Prv value recent
- $205 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.